Condition: Plaque Psoriasis Patients · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
This description comes directly from the study's public registry record.
Alexia Lu · 010-66609745 · CO_HGRAC@innocarepharma.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Completed |
| The Second Affiliated Hospital of Wannan Medical College | Wuhu, Anhui, China | Completed |
| Beijing Chao-Yang Hospital，Capital Medical University | Beijing, Beijing Municipality, China | Completed |
| Beijing Friendship Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Completed |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Completed |
| Beijing Tongren Hospital,CMU | Beijing, Beijing Municipality, China | Completed |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Completed |
| Chongqing Traditional Chinese Medicine Hospital | Chongqing, Chongqing Municipality, China | Completed |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Completed |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, Fujian, China | Completed |
| Dermatology Hospital of Southern Medical University | Guangzhou, Guangdong, China | Completed |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Completed |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06842199